Table 2.

Comparison of treatment for non-small cell lung cancer based on stage between interstitial lung abnormality and interstitial lung disease

	ILA (N = 153)	ILD (N = 114)	P value
Stage 1	N = 66	N = 37
Surgery	53 (80.3)	30 (81.1)	1.000
Radiotherapy	13 (19.7)	3 (8.1)	0.160
Chemotherapy	10 (15.2)	12 (32.4)	0.048
Best supportive care	3 (4.5)	3 (8.1)	0.664
Stage 2	N = 23	N = 11
Surgery	14 (60.9)	7 (63.6)	1.000
Radiotherapy	4 (17.4)	0 (0.0)	0.280
Chemotherapy	6 (26.1)	2 (18.2)	1.000
Best supportive care	4 (17.4)	4 (36.4)	0.388
Stage 3	N = 32	N = 30
Surgery	5 (15.6)	4 (13.3)	1.000
Radiotherapy	8 (25.0)	0 (0.0)	0.005
Chemotherapy	14 (43.8)	14 (46.7)	1.000
Best supportive care	12 (37.5)	14 (46.7)	0.607
Stage 4	N = 32	N = 36
Surgery	2 (6.2)	0 (0.0)	0.218
Radiotherapy	0 (0.0)	3 (8.3)	0.214
Chemotherapy	15 (46.9)	12 (33.3)	0.323
Best supportive care	15 (46.9)	22 (61.1)	0.330

Data are presented as number (%). Patients may receive multiple types of treatment

Best supportive care includes cases where patients choose only best supportive care from the time of lung cancer diagnosis

ILA: interstitial lung abnormality; ILD: interstitial lung disease